Falconer66a If you listen closely Missling is still using the concentration as the metric for the various results.
At the beginning of the presentation he uses dose and then says dose is correlated with concentration and people with higher concentration did better. Later in the presentation he mostly uses concentration as the measure for correlating with results.
If you weren't paying very close attention, you wouldn't pick up on that.
I did like that he discussed the new AD trial as having a number of different biomarkers being measured in the trial. I think these are new biomarkers in AD trials.
I think they are looking for biomarkers that demonstrate improvement as a result of taking 2-73.
Nice. I am also thinking they (Australia) may be using some kind of ERP device (portable-non intrusive) wireless monitoring of patients to get hard data-direct measurements of audio/light/smell/other.
falconer--" Anavex 2-73, at the right dosage, essentially stops the progression of mental decline caused by Alzheimer’s disease"--powerful words indeed---The Aussie Medical Ethics Committee surely is aware of these findings---what is holding up their conditional approval for 2-73 ??? With so many people who could benefit !!!!Anyway to contact them and give them a suggestion ???? I may have to investigate !!